These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22390946)

  • 1. Impact of 5-HT₃ receptor antagonists on peripheral and central diseases.
    Fakhfouri G; Rahimian R; Ghia JE; Khan WI; Dehpour AR
    Drug Discov Today; 2012 Jul; 17(13-14):741-7. PubMed ID: 22390946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT(3) receptors: role in disease and target of drugs.
    Walstab J; Rappold G; Niesler B
    Pharmacol Ther; 2010 Oct; 128(1):146-69. PubMed ID: 20621123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT₃ antagonists under development.
    Chong Y; Choo H
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1309-19. PubMed ID: 20950056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
    Rojas C; Slusher BS
    Eur J Pharmacol; 2012 Jun; 684(1-3):1-7. PubMed ID: 22425650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation.
    Maleki-Dizaji N; Eteraf-Oskouei T; Fakhrjou A; Maljaie SH; Garjani A
    Int Immunopharmacol; 2010 Sep; 10(9):1010-6. PubMed ID: 20646986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of serotonin 5-HT₃ receptors in intestinal inflammation.
    Kato S
    Biol Pharm Bull; 2013; 36(9):1406-9. PubMed ID: 23995650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.
    Fakhfouri G; Mousavizadeh K; Mehr SE; Dehpour AR; Zirak MR; Ghia JE; Rahimian R
    Mol Neurobiol; 2015 Dec; 52(3):1670-1679. PubMed ID: 25377794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in 5-HT3 receptor pharmacology.
    Thompson AJ
    Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system in targeting inflammatory neurodegenerative diseases.
    Centonze D; Finazzi-Agrò A; Bernardi G; Maccarrone M
    Trends Pharmacol Sci; 2007 Apr; 28(4):180-7. PubMed ID: 17350694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
    Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
    Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the 5-HT3A receptor-mediated current by alkyl 4-hydroxybenzoates isolated from the seeds of Nelumbo nucifera.
    Youn UJ; Lee JH; Lee YJ; Nam JW; Bae H; Seo EK
    Chem Biodivers; 2010 Sep; 7(9):2296-302. PubMed ID: 20860031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT
    Fakhfouri G; Rahimian R; Dyhrfjeld-Johnsen J; Zirak MR; Beaulieu JM
    Pharmacol Rev; 2019 Jul; 71(3):383-412. PubMed ID: 31243157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-depressant-like activity of a novel serotonin type-3 (5-HT3) receptor antagonist in rodent models of depression.
    Gupta D; Devadoss T; Bhatt S; Gautam B; Jindal A; Pandey D; Mahesh R
    Indian J Exp Biol; 2011 Aug; 49(8):619-26. PubMed ID: 21870430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides.
    Mahesh R; Devadoss T; Pandey DK; Bhatt S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1253-6. PubMed ID: 21256009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
    Dukat M; Alix K; Worsham J; Khatri S; Schulte MK
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5945-8. PubMed ID: 24035337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARgamma as a therapeutic target in central nervous system diseases.
    Sundararajan S; Jiang Q; Heneka M; Landreth G
    Neurochem Int; 2006 Jul; 49(2):136-44. PubMed ID: 16766086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    Machu TK
    Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential roles of 5-HT
    Zulkifli MH; Viswenaden P; Jasamai M; Azmi N; Yaakob NS
    Biomed Pharmacother; 2019 Apr; 112():108630. PubMed ID: 30797147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.